Masimo (MASI)
(Delayed Data from NSDQ)
$139.94 USD
+4.27 (3.15%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $140.00 +0.06 (0.04%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$139.94 USD
+4.27 (3.15%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $140.00 +0.06 (0.04%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth B Momentum A VGM
Zacks News
Here's Why You Should Add Masimo Stock to Your Portfolio Now
by Zacks Equity Research
MASI's R&D activities raise optimism about the stock.
Reasons to Retain DexCom Stock in Your Portfolio for Now
by Zacks Equity Research
DXCM continues to raise optimism among investors, owing to its strong product portfolio.
Best Momentum Stocks to Buy for October 1st
by Zacks Equity Research
AU, MASI, and SKM made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 1, 2024.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Masimo (MASI) Surges 8.7%: Is This an Indication of Further Gains?
by Zacks Equity Research
Masimo (MASI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
MASI Stock Gains as US Court Raises Concern About Politan's Ethics
by Zacks Equity Research
Shares of Masimo have risen since the news of a court ruling against Politan. The ruling is likely to favor MASI's founder in the upcoming vote for new board members on Sept. 19.
Masimo's Stock Up Following the New Tie-Up With Google to Boost Wear OS
by Zacks Equity Research
MASI's latest partnership is likely to develop a new reference platform that brings high-performing Wear OS smartwatches to market.
Masimo Stock Likely to Rise With Qualcomm Wear OS Partnership
by Zacks Equity Research
MASI Collaborates with Qualcomm to develop a reference platform for Wear OS smartwatches, combining biosensing tech and Snapdragon chips to enhance performance and connectivity.
Zacks Industry Outlook Intuitive Surgical, Masimo and Veracyte
by Zacks Equity Research
Intuitive Surgical, Masimo and Veracyte have been highlighted in this Industry Outlook article
3 Medical Instruments Industry Stocks to Buy on genAI and M&A Boost
by Urmimala Biswas
ISRG, MASI and VCYT from the Zacks Medical Instruments industry are worth buying based on genAI adoption, strategic developments and strong fundamentals. Yet, geopolitical complications and wage and supply issues mar the prospects.
MASI Stock Down Despite New SafetyNet Deal for Neonatal Care
by Zacks Equity Research
The latest adoption of Masimo's SafetyNet is likely to improve the care provided to premature newborns and facilitate their early discharge from the hospital.
Does Masimo (MASI) Have the Potential to Rally 27.46% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Masimo (MASI) points to a 27.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
New Strong Buy Stocks for August 27th
by Zacks Equity Research
LYTS, PDS, STRL, MASI and DEC have been added to the Zacks Rank #1 (Strong Buy) List on August 27, 2024.
Quest Diagnostics' (DGX) New Deal Aids Diagnostic Access in Ohio
by Zacks Equity Research
Quest Diagnostics (DGX) signs an agreement to acquire select assets of University Hospitals' outreach laboratory services business.
Abbott (ABT) Gets FDA Approval for Aspirin-Free HeartMate 3 Regimen
by Zacks Equity Research
Abbott's (ABT) labeling update, exclusively for patients with a HeartMate 3 heart pump, secures the FDA's approval.
Exact Sciences (EXAS) Rides on Cologuard Sales, New Launches
by Zacks Equity Research
Exact Sciences (EXAS) identifies more than 100 opportunities with payers and health systems to address the care gaps with Cologuard through screening programs.
PROCEPT (PRCT) Grows in Urology With FDA Clearance for HYDROS
by Zacks Equity Research
PROCEPT's (PRCT) HYDROS Robotic System leverages AI-driven technology, specifically FirstAssist AI, to optimize treatment planning.
Exact Sciences (EXAS) Enrolls First Patient in Pivotal MCED Study
by Zacks Equity Research
Exact Sciences (EXAS) initiates the MCED Falcon Registry study, with Baylor Scott & White Health and Endeavor Health serving as the primary study sites.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Alcon's (ALC) Market Share Gains, New Launches Aid Growth
by Zacks Equity Research
Alcon (ALC) is witnessing growth in its over-the-counter portfolio, driven by favorable pricing and a sustained family of products.
Walgreens (WBA) Partners With BARDA to Boost Clinical Research
by Zacks Equity Research
Walgreens (WBA) and BARDA form a strategic partnership to bolster the decentralized clinical trial model.
Masimo (MASI) Gets New Suitors for Its Consumer Business Sale
by Zacks Equity Research
Masimo (MASI) receives unsolicited requests from multiple entities for acquiring its consumer business. The company already received a non-binding term sheet confirmation from a third party in May.
Quest Diagnostics (DGX) Debuts Micronutrient Deficiency Panels
by Zacks Equity Research
Quest Diagnostics (DGX) introduces 13 blood tests to identify micronutrient deficiencies.
Bruker (BRKR) Rolls Out the First 1.2 GHz NMR System in Asia
by Zacks Equity Research
Bruker (BRKR) installs the 1.2 GHz Avance NMR Spectrometer at KBSI, enabling advanced scientific discoveries.
Accuray's (ARAY) Radixact for Cancer Treatment Debuts in US
by Zacks Equity Research
Accuray's (ARAY) Radixact System with VitalHold technology is set to enhance precision and comfort in radiation therapy.